Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.

Abstract: Organosilicon compounds bearing carboxylic acid groups are easily and economically replaced in high yield by oxidation of a carbinol-functional organosilicon compound with an oxidizer in the presence of a moderator at a pH?3. Carboxyl-functional organopolysiloxanes highly useful as textile softeners may be obtained by this method.

Abstract: An apparatus and method for carbonylating a reactant, including sequestering Group VIII catalyst metal from a process stream which generally has a ppb concentration of the catalyst metal. The process stream is treated with a polymer having nitrogen-containing heterocyclic repeat units to sequester the catalyst from the stream, thus allowing valuable catalyst to be recovered and returned to the reaction mixture. An apparatus provides a resin bed downstream of the light ends column in a carbonylation process. Preferably, spent resin is regenerated with a regenerant composition compatible with the carbonylation reaction mixture so that catalyst metal can be directly recycled and the resin re-used.

Abstract: The present invention provides a lubricating oil comprising an alicyclic compound represented by a general formula (I): wherein n is an integer of 0 or 1; one of R1 and R2 represents —CH2OR4 (wherein R4 represents a carboxylic acid residue) while the other one represents alkyl, lower alkyl-substituted or unsubstituted cycloalkyl, aryl, or aralkyl; and R3 represents —CH2OR5 (wherein R5 represents a carboxylic residue) and the like. The lubricating oil of the present invention has an excellent traction coefficient, excellent heat resistance, or the like. For the lubricating oil of the present invention, the alicyclic compound represented by the general formula (I) can be directly used as it is, and other base oils such as ester oil, poly-?-olefin, mineral oil, or silicone oil may be included therein, if necessary.

Abstract: A process for the production of fluorinated alkanes by contacting a feed stream containing a fluorinated olefin and a reducing agent, preferably with a first amount of catalyst to produce a fluorinated alkane, at a first conversion level, wherein a first effluent stream contains unreacted fluorinated olefin and reducing agent; and contacting the first effluent stream under conditions effective to produce a higher level of conversion than said conversion level.

Abstract: The present invention relates to oligomeric or polymer dithiophosphate di- or poly-sulfides and their utility in rubbers. Another aspect of the invention is a method for making oligomeric or polymeric dithiophosphates by reacting phosphorous pentasulfide with a di- or polyol and a mono alcohol to produce a dithiophosphoric acid, and then oxidizing the dithiophosphoric acid with an oxidizing agent to produce an oligomeric or polymeric dithiophosphate.

Abstract: The invention relates to a process for preparing polyisocyanates by reacting primary amines with phosgene in the presence of a solvent, wherein ionic liquids are used as solvents.

Abstract: A polyisocyanate production method that can allow effective use of hydrogen chloride produced secondarily in a polyisocyanate production process, while allowing reduction of environmental burdens, and a polyisocyanate production system for performing the polyisocyanate production method. After chlorine is allowed to react with carbon monoxide to produce carbonyl chloride in a carbonyl chloride producing reactor, the carbonyl chloride produced in the carbonyl chloride producing reactor is allowed to react with polyamine in an isocyanate producing reactor to produce polyisocyanate. Then, after hydrochloric gas produced secondarily in the isocyanate producing reactor is purified in a hydrogen chloride purifying column, the purified hydrochloric gas is oxidized in a hydrogen chloride oxidizing reactor to produce chlorine.

Abstract: Disclosed herein is a process to produce an azeotrope composition comprising a hydrofluoroolefin and hydrogen fluoride, said process comprising, dehydrofluorinating a hydrofluorocarbon containing at least one hydrogen and at least one fluorine on adjacent carbons, thereby forming a mixture comprising said hydrofluoroolefin, unreacted hydrofluorocarbon and hydrogen fluoride, and distilling the mixture to produce a distillate composition comprising an azeotrope composition containing said hydrofluoroolefin and hydrogen fluoride and a column bottoms composition comprising said hydrofluorocarbon essentially free of hydrogen fluoride. Also disclosed herein are processes for separation of hydrofluoroolefins from hydrofluorocarbons and from hydrogen fluoride.

Abstract: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Abstract: The present invention is directed to Form II, III, IV and V of sertraline hydrochloride and methods for its preparation. According to the present invention, the various polymorphs of sertraline hydrochloride may be produced either, directly from sertraline base or sertraline acetate.

Abstract: The invention relates to a method for concentrating an aqueous ammonium carbamate stream, which has been formed in a process for the preparation of urea, has a pressure between 0.20 MPa and 0.9 MPa, a temperature between 35° C. and 95° C., and contains at least 25 wt. % H2O, comprising: a pressure increase step, in which the aqueous ammonium carbamate stream is increased in pressure to a pressure between 1.0 MPa and 7 MPa; a condensation step, in which the aqueous ammonium carbamate stream is contacted with a gas stream, which has been formed in a process for the preparation of melamine and which consists essentially of NH3, CO2 and optionally H2O and has a lower H2O content than the aqueous ammonium carbamate stream, the gas stream being absorbed in the aqueous ammonium carbamate stream in such a way that a concentrated ammonium carbamate stream is formed that contains between 15 and 35 wt. % H2O; a discharge step, in which the concentrated ammonium carbamate stream is separated and discharged.

Abstract: Disclosed is a producing method of an optically active ?-amino acid useful as intermediate for the production of medicines, agricultural. chemicals and physiologically active substances, by means of a catalytic and asymmetric synthesis method of high performance and a high enantiomeric excess, without requiring additional procedures such as introduction and removal of protecting group and so on. The method includes subjecting an enamine to an asymmetric hydrogenation.

Abstract: A polyarylene having a structural unit shown by the following formula (1) is disclosed. wherein X and Y indicate a divalent organic group or a single bond, Z shows an oxygen atom or a sulfur atom, R represents at least one atom or group selected from the group consisting of a hydrogen atom, a fluorine atom, an alkyl group, and a fluorine-substituted alkyl group, a is an integer of 1 to 20, n is an integer of 1 to 5, and p is an integer of 0 to 10.

Abstract: The present invention provides an acid addition salt of 5-aminolevulinic acid (5-ALA) or of a 5-ALA derivative (e.g. a 5-ALA ester) with an acid which has a pKa of about 5 or less, preferably about 3 or less, with the proviso that the acid is other than hydrochloric acid. Particularly preferred salts are those derived from acids selected from the group comprising sulphonic acid and its derivatives, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. The salts in accordance with the invention are particularly suitable for use as photosensitizing agents in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body.

Abstract: This invention relates to pharmaceutically acceptable amphiphilic antioxidant compounds, compositions and dosage forms comprising said compounds, and methods and uses reliant on said compounds. The exemplified compounds are all mitoquinone derivatives, being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives. The compounds, compositions, dosage forms, uses and methods are useful in, for example, the treatment of diseases or conditions associated with oxidative stress.

Abstract: The invention provides polymers, methods of preparing polymers, and compositions that include polymers, wherein said polymers include a plurality of two-carbon repeating units in a polymer chain, wherein one or more of the two-carbon repeating units of the polymer chain have a substituent that is covalently bonded to a semifluorinated alkyl ethoxy moiety, and the semifluorinated alkyl ethoxy moiety is attached to the polymer chain substituent through an ester, amide, ketone, carbamate, amine, or other suitable linking group. The polymers can be used to provide antifouling coatings.

Abstract: Cannabinoid derivatives according to formula (I) are disclosed wherein, X, Y, R1, R2, and W can have the definitions provided herein. Without limitation, use of such compounds, their salts or pro-drug, or compositions containing the compounds, salts, or pro-drug, to modify the activity of CB1 and CB2 receptors and treat conditions mediated by these receptors.

Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound.

Abstract: Aspects of the present invention are directed to novel methods for making discrete polyethylene compounds selectively and specifically to a predetermined number of ethylene oxide units. Methods which can be used to build up larger dPEG compounds (a) containing a wider range of utility to make useful homo- and heterofunctional and branched species, and (b) under reaction configurations and conditions that are milder, more efficient, more diverse in terms of incorporating useful functionality, more controllable, and more versatile then any conventional method reported in the art to date. In addition, the embodiments of the invention allow for processes that allow for significantly improving the ability to purify the intermediates or final product mixtures, making these methods useful for commerial manufacturing dPEGs. Protecting groups and functional groups can be designed to make purification at large scale a practical reality.